Table 4.

The use of IL-APIs with beneficial delivery and therapeutic outcomes.

IL-API Formed	Synergism	Efficacy	Reference
Acetyl salicylic acid/salicylate	Improved manufacturing methods Altered side-effect Profile	Solvent-free synthesis Lowered Gastric distress	[14,109,110,111]
Lidocaine docusate	Improved therapeutic outcome	Longer duration of action	[107,112]
Ranitidine docusate	Improved manufacture outcomes	Improved polymorphic challenges	[107]
Didecyldimethylammonium ibuprofenate	Proof of concept	Dual API formation	[107]